Cited by 263Alzheimer's disease research and treatmentsCurcumin's Biomedical ApplicationsNanoparticle-Based Drug Delivery

Multifunctional Nanoliposomes with Curcumin-Lipid Derivative and Brain Targeting Functionality with Potential Applications for Alzheimer Disease

Mourtas, Spyridon, Lazar, Adina N., Markoutsa, Eleni, Duyckaerts, Charles, Antimisiaris, Sophia G.·2014·European Journal of Medicinal Chemistry

Abstract

With the objective to formulate multifunctional nanosized liposomes to target amyloid deposits in Alzheimer Disease (AD) brains, a lipid-PEG-curcumin derivative was synthesized and characterized. Multifunctional liposomes incorporating the curcumin derivative and additionally decorated with a Blood Brain Barrier (BBB) transport mediator (anti-Transferin antibody) were prepared and characterized. The fluorescence intensity of curcumin derivative was found to increase notably when the curcumin moiety was in the form of a diisopropylethylamine (DIPEA) salt. Both curcumin-derivative liposomes and curcumin-derivative Anti-TrF liposomes showed a high affinity for the amyloid deposits, on post-mortem brains samples of AD patients. The ability of both liposomes to delay Aβ1-42 peptide aggregation was confirmed by Thioflavin assay. However, the decoration of the curcumin-derivative liposomes with the Anti-TrF improved significantly the intake by the BBB cellular model. Results verify that the attachment of an antibody on the curcumin-liposome surface does not block deposit staining or prevention of Aβ aggregation, while the presence of the curcumin-PEG-lipid conjugate does not reduce their brain-targeting capability substantially, proving the potential of such multifunctional NLs for application in Alzheimer disease treatment and diagnosis.

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2014.04.050

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mourtas, S., Lazar, A. N., Markoutsa, E., Duyckaerts, C., & Antimisiaris, S. G.
Affiliations
  • University of Patras (GR)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Antimisiaris, Sophia G.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2014-06
Volume
80
Pages
175-183
ISSN
0223-5234 (ISSN-L)
OpenAlex
W2055937873
Cited by
263
References
36
Citations by year
2026: 16 · 2025: 25 · 2024: 21 · 2023: 25 · 2022: 27 · 2021: 31 · 2020: 28 · 2019: 23 · 2018: 21 · 2017: 9 · 2016: 11 · 2015: 21 · 2014: 5
FWCI
10.19
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
Institut National de la Santé et de la Recherche Médicale
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
nanoliposomes, curcumin derivatives, PEG-lipid conjugates, blood-brain barrier targeting, amyloid deposits, Alzheimer's disease, amyloid-beta aggregation, fluorescence imaging, postmortem brain
MeSH terms
Alzheimer Disease, Biological Transport, Blood-Brain Barrier, Brain, Curcumin, Humans, Liposomes, Peptide Fragments, Polyethylene Glycols, Amyloid beta-Peptides, Protein Structure, Secondary, Nanoparticles, Protein Multimerization, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review